Perspective Therapeutics Files 8-K

Ticker: CATX · Form: 8-K · Filed: Oct 20, 2025 · CIK: 728387

Sentiment: neutral

Topics: 8-K, financial-reporting, company-update

TL;DR

Perspective Therapeutics filed an 8-K on 10/20/25 covering financials and other events.

AI Summary

Perspective Therapeutics, Inc. filed an 8-K on October 20, 2025, reporting on its results of operations and financial condition, other events, and financial statements and exhibits. The company, formerly known as Isoray, Inc., is incorporated in Delaware and headquartered in Seattle, WA.

Why It Matters

This filing provides an update on the company's operational and financial status, which is crucial for investors to assess its current performance and future prospects.

Risk Assessment

Risk Level: low — This is a routine filing of an 8-K report, which typically contains factual information without immediate market-moving news.

Key Players & Entities

FAQ

What specific financial results or operational updates are detailed in this 8-K filing?

The filing indicates it covers 'Results of Operations and Financial Condition' but does not provide specific figures within the provided text.

What other events are reported in this 8-K?

The filing lists 'Other Events' as a category of information being reported, but the specifics are not detailed in the provided text.

When was Perspective Therapeutics, Inc. previously known by another name?

The company was formerly known as Isoray, Inc. (name change effective 20181231) and IsoRay, Inc. (name change effective 20050805), and CENTURY PARK PICTURES CORP (name change effective 19920703).

Where is Perspective Therapeutics, Inc. located?

The company's business and mailing address is 2401 Elliott Avenue, Suite 320, Seattle, WA.

What is the Standard Industrial Classification code for Perspective Therapeutics, Inc.?

The SIC code is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 706 words · 3 min read · ~2 pages · Grade level 11.8 · Accepted 2025-10-20 06:02:28

Key Financial Figures

Filing Documents

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On October 20, 2025, Perspective Therapeutics, Inc. (the "Company") issued a press release announcing updated interim results from its Phase 1/2a clinical trial of [ 212 Pb]VMT--NET for the treatment and diagnosis of patients with unresectable or metastatic somatostatin receptor subtype 2-expressing neuroendocrine tumors that are being presented at the European Society for Medical Oncology Congress 2025 taking place October 17-21, 2025 in Berlin, Germany (the "Updated Interim Clinical Results") and certain other business updates (the "Press Release"). The Company also posted to its website a presentation announcing the Updated Interim Clinical Results and certain other business updates (the "Presentation"). The Press Release and the Presentation contain certain estimated and projected financial information, including the Company's estimated cash, cash equivalents and short-term investments as of September 30, 2025. The estimated and projected financial information included in the Press Release and Presentation are preliminary and have not been audited, reviewed or compiled by the Company's independent registered public accounting firm, WithumSmith+Brown, PC ("Withum"), and Withum has not performed any procedures with respect to the preliminary financial data. Accordingly, Withum does not express an opinion or any other form of assurance with respect thereto. The Company's actual results as of September 30, 2025 may differ from the preliminary financial data due to the completion of the Company's closing procedures with respect to the fiscal quarter ended September 30, 2025, final adjustments and other developments that may arise between now and the time the financial results for the fiscal quarter are finalized.

01 Other Events

Item 8.01 Other Events. On October 20, 2025, the Company issued the Press Release. A copy of the Press Release is filed herewith as Exhibit 99.1 and is incorporated by reference into this Item 8.01. Also on October 20, 2025, the Company posted the Presentation to its website. A copy of the Presentation is filed herewith as Exhibit 99.2 and is incorporated by reference into this Item 8.01.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated October 20, 2025 . 99.2 Presentation . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PERSPECTIVE THERAPEUTICS, INC. Date: October 20, 2025 By: /s/ Johan (Thijs) Spoor Johan (Thijs) Spoor Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing